Nuvalent
NUVL
Market cap $5.87B

82.65 USD

-1.20

1.43%

At close Dec 24, 4:00 PM EST

1 day

-1.43%

5 days

-5.94%

1 month

-13.56%

3 months

-18.41%

6 months

2.52%

Year to date

8.61%

1 year

11.24%

5 years

340.80%

10 years

340.80%

About: Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Employees: 127

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,809 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

74% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 27

42% more capital invested

Capital invested by funds: $5.04B [Q2] → $7.15B (+$2.11B) [Q3]

29% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 55

22% more funds holding in top 10

Funds holding in top 10: 9 [Q2] → 11 (+2) [Q3]

12% more funds holding

Funds holding: 172 [Q2] → 192 (+20) [Q3]

3.75% less ownership

Funds ownership: 112.34% [Q2] → 108.59% (-3.75%) [Q3]

30% less call options, than puts

Call options by funds: $46.7M | Put options by funds: $66.5M

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$100

21%

upside

Avg. target

$120

45%

upside

High target

$134

62%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

BMO Capital Etzer Darout 29% 1-year accuracy 12 / 41 met price target	62%upside $134	Outperform Maintained	13 Nov 2024
UBS David Dai 18% 1-year accuracy 2 / 11 met price target	21%upside $100	Neutral Initiated	24 Oct 2024
JP Morgan Anupam Rama 25% 1-year accuracy 15 / 59 met price target	51%upside $125	Overweight Maintained	4 Oct 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about NUVL published over the past 30 days

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Dec. 19, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nuvalent Appoints Grant Bogle to Board of Directors

CAMBRIDGE, Mass. , Dec. 9, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Grant Bogle to its Board of Directors.

Nuvalent Appoints Grant Bogle to Board of Directors

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

CAMBRIDGE, Mass , Nov. 26, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 3:30 p.m.

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

Achievement of all anticipated 2024 milestones and accelerated development timelines reinforce progress on OnTarget 2026 operating plan towards first approved product in 2026 Leading medical oncologist Alice Shaw, M.D., Ph.D. appointed to Scientific Advisory Board Strong cash position of $1.2 billion, including proceeds from upsized $575 million public offering, expected to extend operating runway into 2028 CAMBRIDGE, Mass.

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Nuvalent's lead candidates, NVL-520 and NVL-655, show promising efficacy and safety in Phase 1/2 trials. Both drugs have received FDA Breakthrough Therapy and orphan drug designations, with pivotal Phase 2 data expected in 2025 and potential approvals by 2026. The company completed a $500 million secondary offering, reflecting strong investor interest and providing the cash runway through Phase 3.

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass. , Sept. 18, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its previously announced upsized underwritten public offering of 5,750,000 shares of Class A common stock, which includes 750,000 shares of Class A common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $100.00 per share.

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

Zacks Investment Research

Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?

The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.

Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?

Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases

Nuvalent, Inc. achieved positive data from the phase 1/2 ALKOVE-1 study, using NVL-655 for the treatment of patients with ALK-mutant NSCLC. Positive data achieved from phase 1/2 ARROS-1 study, using zidesamtinib for the treatment of patients with ROS-1 mutant NSCLC. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; 3% to 5% are ALK-positive and then 1% to 3% are ROS-1 positive.

Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass. , Sept. 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of an upsized underwritten public offering of 5,000,000 shares of Class A common stock at a price to the public of $100.00 per share.

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity

Over the weekend, Nuvalent, Inc. NUVL highlighted the presentation of updated data from Phase 1 dose-escalation portions of the ongoing ARROS-1 Phase 1/2 trial of zidesamtinib and ALKOVE-1 Phase 1/2 trial of NVL-655, at the European Society for Medical Oncology (ESMO) Congress 2024.

Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity

See News Rankings

Charts implemented using Lightweight Charts™